Human medicines European public assessment report (EPAR): Trecondi, treosulfan, Hematopoietic Stem Cell Transplantation, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 8 August 2023 - 15:14

Human medicines European public assessment report (EPAR): Trecondi, treosulfan, Hematopoietic Stem Cell Transplantation, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised

Morphine / cyclizine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010549/202210

Submitted by Anonymous (not verified) on 8 August 2023 - 14:40

Morphine / cyclizine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010549/202210

Submitted by Anonymous (not verified) on 8 August 2023 - 14:25

Human medicines European public assessment report (EPAR): Vpriv, velaglucerase alfa, Gaucher Disease, Date of authorisation: 26/08/2010, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 8 August 2023 - 12:54

Human medicines European public assessment report (EPAR): Vpriv, velaglucerase alfa, Gaucher Disease, Date of authorisation: 26/08/2010, Revision: 20, Status: Authorised

Orphan designation: Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase (Bevufenogene nofeparvovec), Treatment of mucopolysaccharidosis type II (Hunter Syndrome), 16/03/2022, Withdrawn

Submitted by Anonymous (not verified) on 8 August 2023 - 12:14

Orphan designation: Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase (Bevufenogene nofeparvovec), Treatment of mucopolysaccharidosis type II (Hunter Syndrome), 16/03/2022, Withdrawn

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More